Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 27, 2016British Journal of Clinical PharmacologyOpen Access

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment

View Full Paper
Ask AI
Bookmark
Share

Authors

BZBaiteng ZhaoSeattle UniversityRCRobert ChenXuzhou Medical CollegeOOOwen A. O’ConnorVirginia Cancer Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhao et al. (2016) studied this question.

synapsesocial.com/papers/6a8bc287f71b672e3df494dfhttps://doi.org/10.1111/bcp.12988
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study2012 · 1,001 citations
  2. 2Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2‐Targeted Antibody‐Drug Conjugate, in Patients With HER2‐Positive Metastatic Breast Cancer2011 · 70 citations
  3. 3Transection of the oesophagus for bleeding oesophageal varices1973 · 8,035 citations
  4. 4cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity2003 · 939 citations
  5. 5Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate2010 · 392 citations